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Prevention, Atlanta, GA, USA
Contemporary public health professionals must address the health needs of a diverse
population with constrained budgets and shrinking funds. Economic evaluation con-
tributes to evidence-based decision making by helping the public health community
identify, measure, and compare activities with the necessary impact, scalability, and
sustainability to optimize population health. Asking “how do investments in public health
strategies influence or offset the need for downstream spending on medical care and/or
social services?” is important when making decisions about resource allocation and
scaling of interventions.
Keywords: economic evaluation, cost analysis, cost-effectiveness analysis, cost-benefit analysis, cost-utility
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In 2012, the United States (U.S.) total health care spending was $2.8 trillion (1). Most were used
to treat diseases rather than prevent them, with only 2.7% dedicated to prevention (1). According
to the National Association for County and City Health Officials and the Association of State and
Territorial Health Officials, local and state health departments cut almost 60,000 public health
jobs from 2008 to 2012 (2, 3). Contemporary public health professionals must address the health
needs of a diverse population with constrained budgets and shrinking funds. It is critical for public
health professionals to use a comprehensive approach to decision-making. This article’s aim is to
provide a framework for use of economic evaluation by public health decision makers at the local,
state, tribal, and national levels. We describe types of economic evaluation and provide examples of
economic evaluation used by two public health research networks, the Centers for Disease Control
and Prevention’s (CDC’s) Prevention Research Centers (PRCs) Program and Robert Wood Johnson
Foundation (RWJF) funded Public Health Practice-Based Research Network (PH-PBRN).
Evidence-Based Public Health and Decision Making
Public health professionals want to improve outcomes and minimize costs; evidence-based public
health (EBPH) is integral in their decision-making process. EBPH is defined as “the develop-
ment, implementation, and evaluation of effective programs and policies in public health through
application of principles of scientific reasoning.” (4) EBPH uses the best available evidence, taking
into consideration the population demographic characteristics, projected or tested program and
intervention impacts, and estimated costs (5, 6). Understanding the economic evidence of public
health intervention is an integral part of EBPH. Economic evidence can provide insight into the
value of public health investments to the overall health system. Evidence suggests that increased
investment in prevention activities and improvements in public health practice and decisionmaking
produce measurable and sustainable health gains (7). A study of local public health agencies in
California from 2001 to 2008 found that a $10 per capita increase in public health investment
could save 9.1 lives per 100,000 (8). This translates to 27,000 deaths per year averted with an
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economic value of $212 billion or more than $100 of benefit for $1
invested (8).
Public health professionals have become skilled at consider-
ing the epidemiologic evidence of health issues. Epidemiology is
the cornerstone of public health, and informs policy decisions
and evidence-based practice by identifying risk factors for dis-
ease and targets for preventive healthcare and interventions. But
public health professionals also have to consider environmental
constraints, such as funding and capacity, when choosing where
to focus efforts. Economic evaluation provides evidence of the
feasibility of intervention scalability and sustainability. Determi-
nation of the costs and benefits of public health interventions
provides data for public health professionals and decision makers
to use when choosing which interventions are effective, efficient,
equitable, scalable, and sustainable (7, 9). Asking “how do invest-
ments in public health strategies influence or offset the need for
downstream spending on medical care and/or social services?”
(10) adds to informed decision making. Yet, economic evaluation
remains a competency gap in public health decision making (11).
To address this competency gap and prepare contemporary public
health professionals, training for a public health profession might
 Offer elective courses on economic evaluation and public
health economics in schools of public health
 Establish more post-doctoral trainings on economic evalua-
tion and public health economics, such as the CDC Preven-
tion Effectiveness Fellowship
 Include economic evaluation inMaster and Doctor of Public
Health (M.P.H. and Dr.P.H.) requirements and
 Provide continuing education for public health professionals
at the local, state, tribal, and national levels through public
health leadership institutes and training centers.
Economic Evaluation
What is economic evaluation? By definition, economics is the
study of decisions, through the examination of program incen-
tives and consequences, and the measure of service production,
delivery, and consumption (12). Economic evaluation is defined
as “the systematic appraisal of costs and benefits of projects,
normally undertaken to determine the relative economic effi-
ciency of programs.” (13) Simply put, economic evaluation is the
understanding and use of economic evidence in decision making.
Economic evaluation contributes to evidence-based decision
making in public health by helping leaders and the commu-
nity identify, measure, and compare activities with the neces-
sary impact, scalability, and sustainability to optimize population
health (13). In the words of Dr. Thomas Frieden, the Director of
the U.S. Centers for Disease Control and Prevention, “to establish
an effective intervention package, it is critical to understand the
full range of available evidence-based strategies, the size and char-
acteristics of the population to be reached, the projected impact of
each intervention, and the estimated cost” (5).
Types of Economic Evaluation and
Decision Levels
There are two levels of economic evaluation: partial and full
(Table 1). Partial economic evaluation measures program or
disease costs, but does not involve a comparison with alternative
options and does not relate costs to outcomes. Partial economic
evaluations include cost-of-illness analysis and program cost anal-
ysis. In public health, full economic evaluation compares two
or more public health interventions through the examination of
costs of inputs and outcomes (14, 15). Full economic evaluations
include cost-benefit, cost-effectiveness, and cost-utility analyses
(14, 15).
Partial Economic Evaluation
a. Cost-of-illness analysis estimates the economic burden or total
costs attributable to a particular disease (14, 15). For example,
the overall U.S. annual direct medical cost of preventing and
treating HPV-associated disease was estimated at $8.0 billion
(2010 USD); of this, total about $7.0 billion was spent on
routine cervical cancer screening and treatment (16).
b. Program cost analysis is a systematic collection and break down
of the cost of a program with descriptions of who or what
entity incurs which costs (14, 15). For example, the cost of
a metformin intervention relative to a placebo intervention
was $2,412 per participant, from a societal perspective over
3 years (17).
Full Economic Evaluation
a. Cost benefit-analysis (CBA) is considered the gold-standard of
economic evaluation because all costs and benefits (and/or
consequences – including health outcomes) are converted to
a common metric such as dollars (14, 15). CBAs are used to
decide among programs with different outcomes (14, 15). For
example, the President, Congress, or a governor all might use
CBA to decide between investments in health vs. another area.
Benefit-cost ratio (BCR) is the summary measure of CBA. A
1.50:1 BCR means for every $1 of cost, society gains $1.50 of
benefits (14, 15).
b. Cost-effectiveness analysis (CEA) compares the costs with nat-
ural health outcome units, such as life-years saved and number
of cases averted (14, 15). For example, a cancer prevention
program director at a local health agency may need to decide
between a number of interventions addressing the same health
outcome. CEAs are appropriate to inform the decision because
they maintain health outcomes in their natural units rather
than monetize the outcome. Cost-effectiveness ratio (CER)
is the summary measure of CEA results, and it is expressed
in costs per natural health units such as dollars per life-year
saved (14, 15). For example, the incremental CER of “Outcome
Monitoring plus Recovery Management Checkups” of adults
with chronic substance abuse inChicago is $23.38 per abstinent
day and $59.51 per reduced substance-related problem (e.g.,
liver disease) (18).
c. Cost-utility analysis (CUA) is a special form of CEA where the
costs and benefits (and/or consequences) are expressed as cost
per a standardized morbidity and mortality measure, such as
quality-adjusted life-year (QALY) (14, 15). QALY is a single
measure of quality of life and survival (15). The summary
measure of a CUA is expressed in cost per QALY (14, 15).
A CUA is appropriate when making a decision at the agency
level, such as the CDC or local health agency, where the direc-
tor decides between public health interventions with different
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TABLE 1 | Types of economic evaluation and decision levels.
Type Description Measures Decision level
PARTIAL ECONOMIC EVALUATION
Cost of illness analysis Disease economic burden Net cost ($) Public health decision-makers at the local, state,
and national levels
Program cost analysis Net program cost Net cost ($) Public health decision-makers at the local, state,
and national levels
First step to CEA, CUA, and CBA
FULL ECONOMIC EVALUATION
Cost-benefit analysis (CBA) Compares different programs with
different outcomes (e.g., health vs.
other area)
Benefit-cost ratio ($benefit: $cost) National level and broader perspective, such as
the President and Congress (e.g.,: Congress
needs to decide between investments in health or
investments for another program)
Cost-effectiveness analysis (CEA) Compares interventions with the same
outcomes (ex: between two cervical
cancer interventions)
Cost-effectiveness ratio ($per case
averted)
Program level (ex: a cancer program director
decides to fund one of two possible cervical
cancer prevention interventions)
Cost utility analysis (CUA) Compares interventions with different
health outcomes (ex: cervical cancer
vs. Alzheimer’s disease)
Cost-utility ratio ($per QALY saved) Agency level (ex: the CDC or a local health
agency director decides between funding cervical
cancer or Alzheimer’s disease interventions)
health outcomes. For example, the cost-utility ratios (i.e., cost
per QALY) of population-wide strategies promoting physical
activity in adults range from $14,000 to $69,000 per QALY
gained (19).
Application of Economic Evaluation in
Public Health
Public health economic evidence can be found in The Cost-
Effectiveness Analysis Registry from Tufts Medical School, (20)
the National Health Services Economic Evaluation Database from
the Cochrane Review, (21) and the Community Guide (22). In
addition, the CDC’s State, Tribal, Local, and Territorial Public
Health Professionals Gateway includes a collection of public
health economics tools and methods (23). The role of eco-
nomic evaluation in public health is gaining attention. However,
it remains an under-used component of evidence-based public
health decision making. In 2012, the Institute of Medicine Com-
mittee on Public Health Strategies to Improve Health Board on
Population Health and Public Health Practice had some specific
recommendations that are a call to action for the use of economic
evidence in public health (24). These recommendations were:
 “Develop a model chart of accounts for use by public health
agencies at all levels to enable better tracking of funding
related to program outputs and outcomes across agencies”
 “Develop a robust research infrastructure for establishing
the effectiveness and value of public health and prevention
strategies”
 “Develop data systems and measures to capture research
quality information on key elements of public health delivery
including program implementation costs”
 “Develop and validate methods for comparing the benefits
and costs of alternative strategies to improve population
health.”
Since these recommendations were given, different efforts are
underway to improve the use of economic evaluation in pub-
lic health practice and decision making. Two examples of these
efforts are the work done by two public health research networks:
the CDC PRC program and the RWJF PH-PBRN.
CDC Prevention Research Centers Program
The PRC program funds through cooperative agreements a
national network of 26 academic research centers that are located
at either a school of public health or a medical school that has a
preventivemedicine residency program. The PRCs are committed
to conducting prevention research and are leaders in translat-
ing research results into policy and public health practice. The
evaluation of the 2014–2019 PRC program added data collec-
tion to complete cost analysis of the core prevention research
projects. As the Director of the CDC PRC program, Dr. Mehran
Massoudi believes the cost analysis is important because “as
scrutiny over federal spending increases with a greater sense
of accountability, the PRC program has the unique opportu-
nity to collect cost data associated with various facets of the
PRCs’ research projects and in turn allow state and local health
departments the ability to consider which components of the
research projects can be adapted and or implemented for their
use.” Dr. Wayne Giles, Director of the CDC’s Division of Pop-
ulation Health in the National Center for Chronic Disease Pre-
vention and Health Promotion (NCCDPHP), added “As we work
to improve the health and wellbeing of populations, it is increas-
ingly important that our interventions demonstrate their ability
to improve the health and delivery of care to populations while
simultaneously addressing costs. Therefore, applied research doc-
umenting cost savings and return on investments are of high
importance.”
The cost analysis will:
 Measure the actual expenditures related to the PRCs’ core
research project
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 Develop capacity of each institution and the PRC program to
use economic evidence to assess the PRC’s research effective-
ness, efficiency, equitability, scalability, and sustainability
 Provide baseline data for further economic evaluation stud-
ies, such as cost-effectiveness analysis and cost-benefit
analysis.
A systematic collection of costs of a PRC’s core research project
was done for the Rural Cancer Prevention Center (RCPC) at the
University of Kentucky. The KY RCPC found that viewing the
1-2-3 Pap video increased the completion rate of human papillo-
mavirus vaccination in 18- to 26-year-old women in Appalachian
Kentucky. A hypothetical adaptation scenario showed that the
intervention cost per completed three vaccination series would
decrease from the efficacy study cost of $890 per completed series
to an estimated implementation cost of $389 per completed series.
Implementation cost estimates of the PRCs’ core research projects
can provide additional evidence to public health practitioners
and decision makers when assessing whether to implement and
scale-up these projects in their communities.
Dr. Jeff Harris, the Principal Investigator for the University of
Washington PRC, believes that “Economic evaluations are quite
important for scaling up applied prevention research. In the short-
term, public health managers need to know what an intervention
will cost. In the long term, they need to knowwhat an intervention
will return.”
RWJF Public Health-Practice Based Research
Network
The PH-PBRN is a nationwide research network composed of
local and state governmental public health agencies, commu-
nity partners, and collaborating academic research institutions.
Through the RWJF’s Delivery and Cost Studies (DACS) Program,
11 PH-PBRNs are conducting studies to estimate the cost of
delivering public health services by examining how characteristics
of public health delivery systems (e.g., activity scope, contributing
organizations’ roles) impact the cost, quality, and equity of public
health services delivery. For example, the Colorado PH-PBRN
estimated the degree to which local public health structural differ-
ences impacted and changed the costs of delivering routine com-
municable disease surveillance by using amicro-costing economic
evaluation method. Results showed that having a dedicated in-
house communicable disease employee reduced spending by $138
per day or $50,370 per year.
Conclusion
In todays’ economic climate of low resources and funding for
public health programs, public health practitioners will benefit
from the use of economic evaluations to enhance public health
evidence-based decisionmaking. Economic evaluation could pro-
vide data to help public health practitioners and decision makers
to identify, measure, and compare a project’s resource allocation
with the project’s impact, scalability, and sustainability to optimize
population health.
As with epidemiology, economic evaluations are becoming
another cornerstone in the foundation of public health decision
making. When asked “why are economic evaluations important
to public health,” Dr. Sam Posner, Associate Director of Science
for CDC’s NCCDPHP, answered “Evaluation of public health
interventions most commonly focuses on the impact on health
outcomes and health status. Evaluating health impact is critical;
however, it is equally important to conduct economic evaluations
of interventions. For public health interventions to result in sus-
tainable change, they need to both be effective in addressing the
health burden and be economically defensible.”
The health of our population will benefit from assuring that
future generations of public health professionals are educated and
trained in economic evaluation. Now, and in the future, it is
essential for public health professionals to understand and use
economic evaluations as part of a comprehensive public health
decision-making process.
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